Inhibrx Biosciences Inc (INBX)
14.90
-0.55
(-3.56%)
USD |
NASDAQ |
Nov 14, 13:13
Inhibrx Biosciences Revenue (Quarterly): 0.10M for June 30, 2024
Revenue (Quarterly) Chart
Historical Revenue (Quarterly) Data
Date | Value |
---|---|
June 30, 2024 | 0.10M |
March 31, 2024 |
Date | Value |
---|---|
June 30, 2023 | 0.03M |
Revenues Definition
Revenues measure the total amount of value that a company brings in during a certain period. This is also considered the "top-line" of the income statement. Revenues are used for all operating expenses as well as other line items which eventually lead to the net income for the company. Revenue is an extremely important metric when analyzing a company. A company with efficient margins is able to turn revenues into the most net income.
Revenue (Quarterly) Range, Past 5 Years
0.03M
Minimum
Jun 2023
0.10M
Maximum
Jun 2024
0.065M
Average
0.065M
Median
Revenue (Quarterly) Benchmarks
CEL-SCI Corp | -- |
AIM ImmunoTech Inc | 0.05M |
IGC Pharma Inc | 0.272M |
NovaBay Pharmaceuticals Inc | 2.40M |
Protalix BioTherapeutics Inc | 13.47M |
Revenue (Quarterly) Related Metrics
Net Income (Quarterly) | 1.858B |
Total Expenses (Quarterly) | 161.00M |
EPS Diluted (Quarterly) | 125.48 |
Enterprise Value | -3.207M |
Earnings Yield | 778.1% |